RSP - Pfizer L3Harris Technologies And More: CNBC's 'Final Trades' | Benzinga
Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE:PFE) as his final trade on the latest edition of CNBC's “Halftime Report Final Trades.”
On Thursday, Pfizer announced it will advance the development of Danuglipron. The company selected the once-daily weight loss drug for continued advancement based on an ongoing pharmacokinetic study.
"Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates," said Mikael Dolsten, chief scientific officer & president, ...